| Literature DB >> 29419532 |
Joann V Pinkerton1, Andra H James2.
Abstract
For women at elevated risk of thrombosis, clinicians are challenged to relieve menopausal symptoms without increasing the risk of thrombosis. Oral menopausal hormone therapy increases the risk of venous thromboembolism by 2-fold to 3-fold. Observational studies suggest less thrombotic risk with transdermal therapies and with progesterone over synthetic progestogens (progestins), but the data are limited. Beneficial nonpharmacologic therapies include cognitive behavioral therapy and clinical hypnosis, whereas beneficial nonhormonal pharmacologic therapies include selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. For treatment of the genitourinary syndrome of menopause, vaginal lubricants and moisturizers, low-dose vaginal estrogen, and intravaginal dehydroepiandrosterone are options.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29419532 DOI: 10.1097/GRF.0000000000000358
Source DB: PubMed Journal: Clin Obstet Gynecol ISSN: 0009-9201 Impact factor: 2.190